Pharmaceutical stocks had a rough session as Novartis shares dropped 11% after Phase 3 trials failed for an Lp(a)-lowering drug. Amgen fell roughly 9%, dragging the Dow Jones lower, while Eli Lilly limited losses with a 2% decline, being less exposed to high-risk trials thanks to its obesity pipeline. JPMorgan maintained Lilly as one of its three top U.S. large-cap biopharma ideas. On Boeing, deliveries totaled 51 aircraft in August, including 41 Boeing 737 Max jets, but year-to-date figures lag annual forecasts with 418 deliveries against a full-year estimate of 659.
Source: Read the original article
